NON RARE IN EUROPE: Tourette syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Feb 2026

ARIPIPRAZOLE: FDA approved

FDAcompleted
Jan 2026ABILIFY MAINTENA: New indication approved
FDAcompleted
Mar 2025ABILIFY MAINTENA: New indication approved
FDAcompleted
Mar 2025ABILIFY MAINTENA: New indication approved
FDAcompleted
Jan 2025ABILIFY MAINTENA: New indication approved
FDAcompleted
Feb 2020ABILIFY MAINTENA: New indication approved
FDAcompleted
Jul 2017ABILIFY MAINTENA: New indication approved
FDAcompleted
Feb 2017ABILIFY MAINTENA: New indication approved
FDAcompleted
Aug 2016ABILIFY MAINTENA: New indication approved
FDAcompleted
Mar 2016

ABILIFY MAINTENA: New indication approved

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for NON RARE IN EUROPE: Tourette syndrome.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Abilify

(aripiprazole)Orphan drug

Otsuka Pharmaceutical Development

Atypical Antipsychotic [EPC]

12.1 Mechanism of Action The mechanism of action of aripiprazole in schizophrenia or bipolar mania, is unclear. However, the efficacy of aripiprazole ...

Approved Dec 2014FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for NON RARE IN EUROPE: Tourette syndrome.
Search all trials →
Search clinical trials for NON RARE IN EUROPE: Tourette syndrome

Recent News & Research

No recent news articles indexed yet for NON RARE IN EUROPE: Tourette syndrome.
Search PubMed for NON RARE IN EUROPE: Tourette syndrome

Browse all NON RARE IN EUROPE: Tourette syndrome news →

Specialist Network

No specialists currently listed for NON RARE IN EUROPE: Tourette syndrome.

View all NON RARE IN EUROPE: Tourette syndrome specialists →

Quick Actions